Three weeks before the September 29 deadline, 100 percent tariffs on patented drug imports loom for every company without an onshoring deal, and three of the industry’s biggest names are still exposed
WASHINGTON, September 7, 2026
The pharmaceutical industry has entered the final three-week countdown to the broadest drug tariff in American history. On September 29, the 100 percent Section 232 duty on imported patented medicines, biologics and their active ingredients extends from the 17 companies already covered to every other importer in the market, and as the deadline bears down this weekend, trade advisers, hospital purchasers and drugmakers are confronting a landscape in which the difference between a zero tariff and a doubled import bill turns on paperwork filed with the Commerce Department months ago.
The stakes sharpened over the past week as compliance specialists and supply chain analysts flagged a striking gap: Pfizer, Johnson & Johnson and GlaxoSmithKline, three of the largest sellers of patented medicines in the United States, remain without confirmed onshoring agreements with the Commerce Department, according to published analyses of the program’s status. Companies and importers that source from manufacturers without approved agreements face the full 100 percent rate on covered products within weeks, a cost shock that would ripple from wholesale contracts to insurance formularies to hospital budgets.
How the Cliff Was Built
The structure now approaching its full-force date was established on April 2, 2026, when President Trump signed Proclamation 11020 under Section 232 of the Trade Expansion Act of 1962, the same national security statute underpinning the administration’s steel, aluminum, semiconductor and copper tariffs. The proclamation determined that imports of certain pharmaceuticals and pharmaceutical ingredients threaten to impair US national security and imposed a headline duty of 100 percent on patented and branded drugs, biologics and their active pharmaceutical ingredients.
The program’s design is deliberately coercive in the way the administration has made its signature: a punishing default rate paired with deep discounts for companies that relocate production. Importers with a Commerce-approved onshoring plan see the rate fall from 100 percent to 20 percent. Companies that additionally sign most-favored-nation pricing agreements with the Department of Health and Human Services, committing to charge US buyers no more than the lowest price offered in peer nations, qualify for a zero rate through January 20, 2029.
Implementation came in two waves. The 17 multinational drugmakers named in Annex III of the proclamation, the industry’s largest importers by value, became subject to the tariff on July 31. Everyone else received an extension to September 29. Applications for onshoring agreements were due to the Commerce Department by June 12, and the department subsequently published procedures allowing remaining companies to apply. With the second effective date now three weeks out, the program is about to convert from a large-company problem into an economy-wide one.
Who Is Exposed
The carve-outs define the blast radius as much as the duty does. Generic pharmaceuticals, biosimilars and their associated ingredients are expressly excluded from the Section 232 program, a decision that spares roughly 90 percent of US prescriptions by volume and provides substantial insulation to generic powerhouses in India, whose industry ships billions of dollars in finished doses to the American market. The exclusion reflects a political reality: a tariff that doubled the cost of generic metformin or atorvastatin would have been felt at every pharmacy counter in the country within weeks.
Country-level arrangements further tier the exposure. Patented drugs and ingredients from the United Kingdom carry a 10 percent rate under the US-UK trade framework, while comparable products from the European Union, Japan, South Korea, Switzerland and Liechtenstein face 15 percent, ceilings negotiated in last year’s trade agreements that function as a shield for the European and East Asian manufacturing bases of the global industry. The 100 percent rate therefore lands hardest on patented products and ingredients from everywhere else, and on any company, regardless of headquarters, that lacks both a qualifying trade-agreement origin and an onshoring deal.
That is what makes the position of the three holdout majors so consequential. Analyses published by trade and supply chain advisory firms, including Exiger and law firm client alerts circulating through the summer, identified Pfizer, Johnson & Johnson and GSK as the Annex III companies without confirmed Commerce onshoring agreements. Johnson & Johnson has announced a 55 billion dollar US manufacturing investment program through 2029, but a corporate capital commitment is not the same instrument as an executed onshoring agreement under the proclamation’s terms, and the company’s tariff status on covered import lines remains unresolved in public reporting. Hospital systems and wholesalers that buy from the three companies have spent recent weeks pressing for clarity on which products ship from covered origins and who bears the duty if the cliff arrives first.
The Scramble in the Supply Chain
The behavioral response across the industry has followed a predictable playbook, visible in trade data and corporate disclosures all year. The first move was inventory: drugmakers front-loaded US imports of patented products through the spring and early summer, building stockpiles ahead of the July 31 and September 29 dates in a surge that at times distorted monthly trade statistics for pharmaceutical categories. Warehousing patented biologics is costlier and harder than warehousing pills, given cold chain requirements, but analysts estimate many large firms entered the third quarter holding six months or more of US inventory on key lines.
The second move was sourcing. Companies with flexible manufacturing networks have shifted production of US-bound patented products toward sites in the United Kingdom, European Union, Japan, South Korea and Switzerland to capture the 10 and 15 percent trade-agreement ceilings, and away from facilities in jurisdictions with no protective arrangement. Contract development and manufacturing organizations with American capacity report order books stretching years out, and industry surveys describe a fragmentation of supply networks as firms split production of single products across multiple regions to hedge tariff outcomes.
The third move is the one the administration wanted: onshoring commitments. Since April, the sector has announced a wave of US capital projects, from active ingredient plants to fill-finish capacity, that collectively run into the hundreds of billions of dollars when combined with commitments announced in 2025. Eli Lilly, Novartis, Roche, AstraZeneca and others among the Annex III group moved early to secure agreements and the reduced 20 percent or zero rates that accompany them. Recruiting analysts tracking the sector note that life sciences hiring in manufacturing engineering, quality assurance and regulatory affairs has accelerated in states landing the new plants, even as the industry warns that a fill-finish line takes three to five years to license and validate, so the jobs arrive years before the tariff-relieving production does.
What It Means for Prices and Patients
The consumer-facing question, whether medicine prices rise, has a more complicated answer than the tariff’s size suggests. Patented drug pricing in the United States is mediated by pharmacy benefit managers, rebates and confidential contracts, so a doubled import cost does not translate mechanically into a doubled list price. Manufacturers of high-margin patented products can absorb meaningful duty costs on some lines, and the MFN pricing pathway explicitly trades tariff relief for price restraint, meaning some covered drugs could see US prices fall under the program’s logic.
But absorption has limits, and the pressure points are identifiable. Hospital-administered biologics, infused oncology products and specialty medicines with concentrated foreign production and no near-term US alternative are the categories analysts flag for cost pass-through into hospital charge masters and insurance premiums over the next two years. Payers and provider groups have warned that a 100 percent duty applied to even a narrow set of high-cost biologics would strain hospital pharmacy budgets already contending with drug spending growth. The National Association of Chain Drug Stores and hospital associations have pressed the administration for monitoring and relief mechanisms if shortages or price spikes emerge in specific therapeutic classes.
Employers and insurers are already pricing the uncertainty. Benefits consultants advising large self-insured employers on 2027 plan design report building in specialty drug trend assumptions one to three percentage points higher than they otherwise would, explicitly citing tariff pass-through risk on infused and injected biologics. State Medicaid programs, which purchase under statutory rebate formulas, have asked federal regulators how tariff-driven cost increases interact with best-price rules, a technical question with hundreds of millions of dollars riding on the answer. None of these costs appear in the tariff’s revenue arithmetic, but all of them land, eventually, on premiums and public budgets.
Shortage risk is the quieter worry among supply chain professionals. The tariff excludes generics, but patented sterile injectables and complex biologics have thin, concentrated supply chains, and a company facing a 100 percent duty on a marginal product line has a straightforward incentive to deprioritize the US market for that line rather than pay or relocate. The Food and Drug Administration’s drug shortage staff and Commerce officials have reportedly established coordination channels to watch for discontinuation signals as the September 29 date passes, though no formal safety valve exists in the proclamation itself.
The Global Ripple: Ireland, Switzerland, Singapore, India
The tariff’s geography of pain maps onto the peculiar globalization of drug manufacturing, an industry that concentrated production in a handful of tax-advantaged and specialized jurisdictions over three decades. Ireland is the most exposed economy in absolute terms: pharmaceuticals and organic chemicals account for the largest share of Irish goods exports to the United States, driven by American multinationals that domiciled blockbuster production there. Irish officials and industry groups have spent the year quantifying scenarios in which US-bound production migrates to new American plants, taking corporation tax revenue with it, though the EU’s negotiated 15 percent ceiling blunts the immediate blow relative to the 100 percent headline.
Switzerland’s position is similar in kind: its 15 percent ceiling shelters the Basel giants’ Swiss production, and both Novartis and Roche coupled large American investment announcements to their onshoring negotiations earlier this year. Singapore, a major API and biologics node without an equivalent arrangement, has pressed Washington for one. And India occupies the strangest position of all: its dominant generics industry is excluded from the program entirely, while its ambitions in patented biosimilars and novel drugs sit squarely inside it, one more thread in the bilateral trade negotiation now stalled over preferential rates.
The two-tier country structure also creates arbitrage incentives that customs authorities are preparing to police. A patented drug’s tariff exposure follows its country of substantial transformation, typically where the active ingredient is synthesized or the biologic is produced, not where it is packaged. Trade advisers report a surge in tariff engineering inquiries: whether moving a final synthesis step, a formulation stage or a fill-finish operation into a 15 percent jurisdiction, or into the United States itself, changes the origin determination. Customs and Border Protection has signaled that it will scrutinize transformation claims on pharmaceutical entries closely, and misclassification penalties in a 100 percent duty environment are severe enough to make conservative counsel the norm.
Lessons from Steel: What Section 232 History Predicts
The pharmaceutical program is the most ambitious use of Section 232 since the statute’s revival, and the eight-year track record of its steel and aluminum predecessors offers a preview of the dynamics now beginning in drugs. The steel tariffs, imposed at 25 percent in 2018 and raised to 50 percent this year, did stimulate domestic investment and capacity announcements. They also generated a sprawling exclusion-request apparatus, persistent litigation, downstream cost complaints from metal-using manufacturers, and retaliation from trading partners. Nearly a decade on, they remain in force, having outlasted the administration that imposed them, the one that followed, and every prediction of their imminent negotiation away.
Applied to pharmaceuticals, that history suggests three things. First, durability: companies structuring supply chains around the hope of near-term repeal are likely misreading the instrument. Second, accretion: Section 232 programs tend to expand, as the steel program did into derivative articles, and the proclamation’s architecture already contemplates additional product listings, with the administration studying extensions into medical devices and additional ingredient categories. Third, institutionalization: the exclusion and agreement processes become permanent features of doing business, with the Commerce Department functioning as gatekeeper of effective rates company by company, a form of administrative discretion that industry lawyers note has no close precedent at this scale in the pharmaceutical sector.
The revenue dimension is not trivial either. The United States imported roughly 200 billion dollars in pharmaceutical products in 2024, the largest category of goods imports after machinery and electronics. Even with generics excluded and trade-agreement ceilings capping much of the patented flow at 10 to 15 percent, the program is projected to raise tens of billions of dollars annually while the onshoring transition plays out, receipts the administration has cited in defense of its broader tariff architecture.
The Legal and Political Terrain
Unlike the administration’s defunct IEEPA tariffs, struck down by the Supreme Court in February in Learning Resources v. Trump, the pharmaceutical program rests on Section 232, the national security authority the Court’s ruling left intact and elevated. Legal challenges to Section 232 actions have historically failed on deference grounds, and trade lawyers broadly advise clients to plan around the tariff’s durability rather than its litigation risk. A Section 232 measure persists until a president affirmatively finds the national security threat resolved, and it survives changes of administration absent deliberate action.
Politically, the program has become the administration’s template. Commerce Secretary Howard Lutnick confirmed this week at the G20 Innovation Ministerial that the forthcoming Phase Two semiconductor tariffs will follow the pharmaceutical model explicitly, telling interviewers that companies that built innovative pharmaceuticals in America and accepted MFN pricing received tariff relief, and that the same structure is what industry should expect for chips. The pharmaceutical cliff, in other words, is no longer just a pharmaceutical story: it is the proof of concept for a tariff architecture the administration intends to replicate across strategic sectors.
Congressional reaction remains divided along familiar lines. Supporters credit the program with the largest wave of domestic pharmaceutical investment announcements on record and note that no significant shortage has yet materialized. Critics, including some Republicans from districts with heavy hospital employment, warn that the September 29 extension of the duty to hundreds of smaller importers, specialty distributors and mid-cap biotechs, entities with far less capacity to relocate production or negotiate with Commerce than the Annex III giants, is where the program’s costs will surface first.
The Onshoring Scoreboard
The clearest measure of the program’s coercive success is the capital it has moved. Since the April proclamation, and building on commitments that began accumulating in 2025 when the tariff threat first firmed, the industry’s announced US manufacturing investments have reached a scale without precedent in the sector’s history. Eli Lilly has committed to a multi-site American expansion program its executives value at more than 50 billion dollars, including new API facilities intended to repatriate small-molecule ingredient synthesis that migrated to Asia decades ago. Johnson & Johnson’s 55 billion dollar program, AstraZeneca’s 50 billion dollar pledge, and multibillion-dollar commitments from Novartis, Roche, Sanofi, Bristol Myers Squibb and GSK round out a list that collectively exceeds 350 billion dollars in announced spending through the end of the decade, according to tallies maintained by industry publications.
The caveats are the same ones attached to every investment-announcement wave: announced is not built, built is not licensed, and licensed is not producing. A greenfield biologics plant takes five to seven years from groundbreaking to validated commercial output under FDA good manufacturing practice requirements, and the industry’s own reshoring analyses concede that American API capacity for many older molecules cannot be economic without sustained policy support. The administration argues that is precisely what a permanent Section 232 program provides. Skeptics note that the January 20, 2029 expiration of the zero-rate MFN window creates a cliff of its own, timed suspiciously close to the end of the presidential term, after which every company’s effective rate becomes a new negotiation.
Three Weeks Out: The Checklist
For importers, the guidance circulating from customs brokers and trade counsel this week is concrete. First, classify: confirm which imported products are patented or branded drugs, biologics or covered active ingredients, and which qualify as excluded generics or biosimilars. Second, trace origin: a product’s tariff exposure follows its country of substantial transformation, and the 10 and 15 percent trade-agreement ceilings can dramatically reduce liability for UK, EU, Japanese, Korean and Swiss production. Third, verify supplier status: importers buying from manufacturers with approved onshoring agreements inherit the reduced rate on covered lines, so confirming a supplier’s standing with Commerce is now a due diligence item on par with quality audits. Fourth, model the duty in contracts: wholesale agreements written before April rarely specify who bears a Section 232 duty, and disputes over tariff allocation clauses are already reaching trade counsel.
The broader lesson the market is absorbing, three weeks before the cliff, is that the administration’s tariff program has matured from blunt instrument to conditional architecture. The 100 percent rate is designed never to be widely paid; it is designed to make the 20 percent onshoring rate, the zero MFN rate and the billions in American plant announcements look like bargains. Whether that architecture delivers resilient domestic drug production before it delivers price and supply disruptions is the question the next three weeks will begin to answer, and on September 29 the answer stops being theoretical.